Zoetis Inc. (NYSE:ZTS) Given Average Rating of “Hold” by Analysts

Zoetis Inc. (NYSE:ZTS) has earned a consensus recommendation of “Hold” from the thirteen analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $152.9091.

ZTS has been the subject of a number of research analyst reports. Piper Sandler restated a “neutral” rating and set a $135.00 price objective (down previously from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Bank of America boosted their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Finally, KeyCorp initiated coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock.

Zoetis Stock Performance

ZTS stock opened at $128.73 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market cap of $54.34 billion, a PE ratio of 21.38, a P/E/G ratio of 1.97 and a beta of 0.96. The business has a 50 day moving average of $125.41 and a 200-day moving average of $134.64. Zoetis has a 12-month low of $115.25 and a 12-month high of $177.00.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts expect that Zoetis will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.6%. Zoetis’s dividend payout ratio is 35.22%.

Institutional Trading of Zoetis

Institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. raised its holdings in Zoetis by 3,311.3% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 158,250 shares of the company’s stock valued at $19,912,000 after acquiring an additional 153,611 shares during the period. Strive Financial Group LLC purchased a new position in shares of Zoetis in the fourth quarter valued at $390,000. Beacon Pointe Advisors LLC raised its stake in shares of Zoetis by 3.6% during the 4th quarter. Beacon Pointe Advisors LLC now owns 9,525 shares of the company’s stock valued at $1,198,000 after purchasing an additional 327 shares during the period. First Citizens Bank & Trust Co. raised its stake in shares of Zoetis by 34.8% during the 4th quarter. First Citizens Bank & Trust Co. now owns 58,495 shares of the company’s stock valued at $7,360,000 after purchasing an additional 15,115 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in Zoetis during the 4th quarter worth about $35,365,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.